FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?

D. P. Modest; U. P. Neumann; J. Pratschke

doi:10.1016/j.ejca.2016.12.005

FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?

D. P. Modest^*, U. P. Neumann, J. Pratschke

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	71-73
Number of pages	3
Journal	European Journal of Cancer
Volume	73
DOIs	https://doi.org/10.1016/j.ejca.2016.12.005
Publication status	Published - Mar 2017

Keywords

EARLY TUMOR SHRINKAGE
RESECTION
CHEMOTHERAPY
CETUXIMAB
SURVIVAL
DISEASE
TRIAL

Access to Document

10.1016/j.ejca.2016.12.005

Cite this

@article{6b5e4c59a6a74e3d9bda3ec05f59acb8,

title = "FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?",

keywords = "EARLY TUMOR SHRINKAGE, RESECTION, CHEMOTHERAPY, CETUXIMAB, SURVIVAL, DISEASE, TRIAL",

author = "Modest, \{D. P.\} and Neumann, \{U. P.\} and J. Pratschke",

year = "2017",

month = mar,

doi = "10.1016/j.ejca.2016.12.005",

language = "English",

volume = "73",

pages = "71--73",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer

T2 - A necessity?

AU - Modest, D. P.

AU - Neumann, U. P.

AU - Pratschke, J.

PY - 2017/3

Y1 - 2017/3

KW - EARLY TUMOR SHRINKAGE

KW - RESECTION

KW - CHEMOTHERAPY

KW - CETUXIMAB

KW - SURVIVAL

KW - DISEASE

KW - TRIAL

U2 - 10.1016/j.ejca.2016.12.005

DO - 10.1016/j.ejca.2016.12.005

M3 - Editorial

C2 - 28081915

SN - 0959-8049

VL - 73

SP - 71

EP - 73

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -